Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Open Medicine

formerly Central European Journal of Medicine

Editor-in-Chief: Darzynkiewicz, Zbigniew


IMPACT FACTOR 2018: 1.221

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.329
Source Normalized Impact per Paper (SNIP) 2018: 0.479

ICV 2017: 152.94

Open Access
Online
ISSN
2391-5463
See all formats and pricing
More options …
Volume 9, Issue 2

Issues

Volume 10 (2015)

Significance of GRP78 expression in acute myeloid leukemias

Tomasz Wróbel
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4 Street, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Ewa Stefanko
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4 Street, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Justyna Dzietczenia
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4 Street, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Bożena Jaźwiec
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4 Street, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Grzegorz Mazur
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4 Street, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Olga Haus
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4 Street, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Jarosław Dybko
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4 Street, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Kazimierz Kuliczkowski
  • Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wroclaw Medical University, Pasteura 4 Street, 50-367, Wroclaw, Poland
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-02-13 | DOI: https://doi.org/10.2478/s11536-013-0200-7

Abstract

The GRP78 (glucose-regulated protein 78) is a major endoplasmic reticulum (ER) chaperone facilitating proper folding of the newly synthesized proteins. By the interaction with caspases, GRP78 has antiapoptotic properties allowing cells to survive under stress condition. GRP78 expression and its association with tumor proliferation, metastasis and resistance to chemotherapy were observed in solid tumors. There are limited data on the expression and impact of this protein on the clinical course and treatment response in acute myeloid leukemia (AML). The aim of this study was to evaluate the expression of GRP78 mRNA in patients with de novo AML. These results were compared to healthy controls, blast phenotype, molecular and cytogenetic status and clinical features of AML. 101 non-M3 AML patients and 26 healthy individuals were included in this study. The expression of GRP78 mRNA in bone marrow was analyzed by real-time quantitative polymerase chain reaction (RQ-PCR). We demonstrated increased GRP78 mRNA expression in AML patients compared to healthy controls, although this difference was statistically significant only in CD34+ leukemias. There was also no significant correlation between GRP78 mRNA expression and complete remission rate, relapse-free survival and overall survival. These results indicate that GRP78 expression is increased in CD34+ leukemias and has no prognostic impact on clinical outcome in AML.

Keywords: Acute myeloid leukemia; GRP78; Resistance to chemotherapy

  • [1] Christ O, Feuring-Buske M, Hiddemann W et al. Pathobiology of acute myeloid leukemia. Med Clin. 2007; 102:290–295 Google Scholar

  • [2] Schroder M, Kauffman RJ. ER stress and the unfolded protein response. Mutat Res 2005; 569:29–63 http://dx.doi.org/10.1016/j.mrfmmm.2004.06.056CrossrefGoogle Scholar

  • [3] Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007; 8:519–529 http://dx.doi.org/10.1038/nrm2199Web of ScienceCrossrefGoogle Scholar

  • [4] Fu Y, Lee AS. Glucose regulated proteins in cancer progression, drug resistance and immunotherapy. Cancer Biol Ther. 2006; 5:741–744 http://dx.doi.org/10.4161/cbt.5.7.2970CrossrefGoogle Scholar

  • [5] Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. A report of the French-American-British (FAB) cooperative group. Ann Intern Med. 1985;103:620–625 http://dx.doi.org/10.7326/0003-4819-103-4-620CrossrefGoogle Scholar

  • [6] Döhner H, Estey EH, Amadori S et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010; 115: 453–474 http://dx.doi.org/10.1182/blood-2009-07-235358CrossrefGoogle Scholar

  • [7] Hołowiecki J, Grosicki S, Robak T et al. Polish Adult Leukemia Group (PALG). Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III Study. Leukemia. 2004; 18:989–997 CrossrefGoogle Scholar

  • [8] Hołowiecki J, Grosicki S, Kyrcz-Krzemien S et al. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome—Polish Adult Leukemia Group (PALG) pilot study. Ann Hematol. 2008; 81:361–367 http://dx.doi.org/10.1007/s00277-007-0421-4CrossrefGoogle Scholar

  • [9] Hołowiecki J, Grosicki S, Robak T et al. Daunorubicin, Cytarabine, and 2CdA (DAC-7) for remission indiction in “de novo” Adult Acute Myeloid Leukemia Patients. Acta Haematol Pol. 2001; 2002:839–847 Google Scholar

  • [10] Yates J, Glidewell O, Wiernik P et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study. Blood. 1982; 60:454–462 Google Scholar

  • [11] Wrzesień-Kus A, Robak T, Jamroziak K et al. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients — a report of Polish Acute Leukemia Group (PALG) phase II study. Neoplasma. 2002; 49:405–411 Google Scholar

  • [12] Byrd JC, Mrózek K, Dodge RK et al. Cancer and Leukemia Group B(CALGB 8461). Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100: 4325–4336 http://dx.doi.org/10.1182/blood-2002-03-0772CrossrefGoogle Scholar

  • [13] Castaigne S, Chevret S, Archimbaud E et al. Randomized comparison of double induction and timed-sequential induction to a “ 3+7” induction in adults with AML; long term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004; 104: 2467–2474 http://dx.doi.org/10.1182/blood-2003-10-3561CrossrefGoogle Scholar

  • [14] Jurisic V, Srdic-Rajic T, Konjevic G et al. TNF-α induced apoptosis is accompanied with rapid CD30 and slower CD45 shedding from K-562 cells. J Membr Biol. 2011; 239:115–122 http://dx.doi.org/10.1007/s00232-010-9309-7Web of ScienceCrossrefGoogle Scholar

  • [15] Xing X, Lai M, Wang Y et al. Overexpression of glucose-regulated protein 78 in colon cancer. Clin Chim Acta. 2006; 364:308–315. http://dx.doi.org/10.1016/j.cca.2005.07.016CrossrefGoogle Scholar

  • [16] Fernandez PM, Tabbara SO, Jacobs LK et al. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat. 2000; 59:15–26 http://dx.doi.org/10.1023/A:1006332011207CrossrefGoogle Scholar

  • [17] Arap MA, Lahdenranta J, Mintz PJ et al. Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands. Cancer Cell. 2004; 6:275–284 http://dx.doi.org/10.1016/j.ccr.2004.08.018CrossrefGoogle Scholar

  • [18] Uramoto H, Sugio K, Oyama T et al. Expression of endoplasmic reticulum molecular chaperone Grp78 in human lung cancer and its clinical significance. Lung Cancer. 2005; 49: 55–62 http://dx.doi.org/10.1016/j.lungcan.2004.12.011CrossrefGoogle Scholar

  • [19] Tanimura A, Yujiri T, Tanaka Y et al. Activation of the unfolded protein response in primary acute myeloid leukemia cells. Int J Hematol. 2011; 94:300–302 http://dx.doi.org/10.1007/s12185-011-0918-4CrossrefGoogle Scholar

  • [20] Valk PJ, Verhaak RG, Beijen MA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004; 350:1617–1628 http://dx.doi.org/10.1056/NEJMoa040465CrossrefGoogle Scholar

  • [21] Schardt JA, Weber A, Eyholzer M et al. Activation of the unfolded protein response is associated with favorable prognosis in acute myeloid leukemia. Clin Cancer Res. 2009; 15:3834–3841 http://dx.doi.org/10.1158/1078-0432.CCR-08-2870CrossrefGoogle Scholar

  • [22] Khan MM, Nomura T, Chiba T et al. The fusion oncoprotein PML-RARalpha induces endoplasmic reticulum (ER)-associated degradation of N-CoR and ER stress. J Biol Chem. 2004; 279:11814–11824 http://dx.doi.org/10.1074/jbc.M312121200CrossrefGoogle Scholar

  • [23] Jordan CT. The leukemic stem cell. Best Pract Res Clin Haematol 2007; 20:13–18 http://dx.doi.org/10.1016/j.beha.2006.10.005CrossrefGoogle Scholar

  • [24] Ota J, Yamashita Y, Okawa K et al. Proteomic analysis of hematopoietic stem cell-like fractions in leukemic disorders. Oncogene. 2003; 22:5720–5728 http://dx.doi.org/10.1038/sj.onc.1206855CrossrefGoogle Scholar

  • [25] Bagratuni T, Wu P, Gonzalez de Castro D et al. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010; 116:250–253 http://dx.doi.org/10.1182/blood-2010-01-263236Web of ScienceCrossrefGoogle Scholar

  • [26] Bhojwani D, Kang H, Moskowitz NP et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood. 2006; 108:711–717 http://dx.doi.org/10.1182/blood-2006-02-002824CrossrefGoogle Scholar

  • [27] Schardt JA, Mueller BU, Pabst T et al. Activation of unfolded protein response in human acute myeloid leukemia. Methods Enzymol. 2011; 489:227–243 http://dx.doi.org/10.1016/B978-0-12-385116-1.00013-3Web of ScienceCrossrefGoogle Scholar

About the article

Published Online: 2014-02-13

Published in Print: 2014-04-01


Citation Information: Open Medicine, Volume 9, Issue 2, Pages 204–209, ISSN (Online) 2391-5463, DOI: https://doi.org/10.2478/s11536-013-0200-7.

Export Citation

© 2014 Versita Warsaw. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Comments (0)

Please log in or register to comment.
Log in